Academic Journal
Q1Liver Cancer
About Liver Cancer
Liver Cancer is a scholarly journal published by S. Karger AG. SCImago 2025 lists it in Q1, with an SJR of 3.334 and H-index of 69.
Coverage: 2009, 2012-2026. Research categories: Hepatology (Q1); Oncology (Q1).
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Scope information will be added after verification.
Recent Research Articles
Latest publications matched automatically by ISSN.
Deep Response as a Novel Efficacy Endpoint in Hepatocellular Carcinoma
Masatoshi Kudo
2026-07-30 · DOI: 10.1159/000553391Exposure to Poly- and Perfluoroalkyl Substances and Risk of Hepatocellular Carcinoma in Male Patients with Cirrhosis Related to Hepatitis C Virus Infection
Aaron P. Thrift, Noura Abdulrahman, Priya B. Shetty, Hyeyeun Lim et al.
2026-07-11 · DOI: 10.1159/000551746Selective Conventional Transarterial Chemoembolization Using a Glass Membrane Emulsification Device in Hepatocellular Carcinoma: Multicenter Clinical Trial in Japan
Toshihiro Tanaka, Hiroshi Anai, Tetsuya Masada, Satoru Sueyoshi et al.
2026-07-10 · DOI: 10.1159/000552424Lenvatinib versus Sorafenib in First-Line Treatment of Older Patients with Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial
Masatoshi Kudo, Arndt Vogel, Thomas R. Jeffry Evans, Yuk Ting Ma et al.
2026-07-04 · DOI: 10.1159/000553375An updated systematic review and meta-analysis of modern radiotherapy techniques for hepatocellular carcinoma
Sun Hyun Bae, Won Il Jang, Jeong Il Yu, Ji Eun Moon et al.
2026-07-02 · DOI: 10.1159/000552470Alcohol Plays a Detrimental Role in the Prognosis of Hepatocellular Carcinoma Related to Steatotic Liver Disease
Stefano Gitto, Alessandro Vitale, Gianluca Svegliati-Baroni, Giulio Marchesini et al.
2026-07-02 · DOI: 10.1159/000553063Carvedilol versus Propranolol in Patients with Hepatocellular Carcinoma: A Nationwide Cohort Study
Byeong Geun Song, Myeongcheol Lee, Juhee Cho, Geum-Youn Gwak et al.
2026-06-29 · DOI: 10.1159/000553325The Regeneration Paradox in Liver Cancer: How Chronic Injury Transforms Healing into Carcinogenesis
Chun-Nan Yeh, Miin-Fu Chen
2026-06-25 · DOI: 10.1159/000550897Acquired Genetic Variants, Not Tumor Mutation Burden, Drive Resistance to Immunotherapy in Hepatocellular Carcinoma
Jinho Lee, Hye Won Lee, Mi Ri Park, Saeam Shin et al.
2026-06-16 · DOI: 10.1159/000553049Reply to “Methodological Concerns in ‘Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma’”
Da-Long Yang, Jian-Li Huang, Hong-Gui Qin, Liang Ma et al.
2026-06-11 · DOI: 10.1159/000553001Reply to the Comment on the Article “Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor Based Combination Therapy for Unresectable Hepatocellular Carcinoma”
Zhi-Hao Huang, Jian-Li Huang, Lei-Po Lin, Da-Long Yang et al.
2026-06-11 · DOI: 10.1159/000553004Lenvatinib Added to Nivolumab and Ipilimumab Improves Tumor Control and Progression-Free Survival in Unresectable Hepatocellular Carcinoma
Kuan-Chang Lai, Chien-An Liu, Hao-Jan Lei, San-Chi Chen et al.
2026-06-09 · DOI: 10.1159/000552861Definition of Conversion Therapy and Neoadjuvant Therapy for Hepatocellular Carcinoma: A Consensus Guideline from the Japan Liver Cancer Association
Akihiko Ichida, Ryosuke Tateishi, Etsuro Hatano, Akinobu Taketomi et al.
2026-06-09 · DOI: 10.1159/000552928Dissecting the Transcriptomic Profile of CD163 + Macrophages in Hepatocellular Carcinoma with VETC + Angiogenesis Provides Potential Targets of Treatment
Camilla De Carlo, Anna Rita Putignano, Reha Akpinar, Barbara Durante et al.
2026-06-08 · DOI: 10.1159/000552648Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study
Masayuki Ueno, Yung-Yeh Su, Atsushi Takai, Yi-Hsiang Huang et al.
2026-06-01 · DOI: 10.1159/000552808Hepatic Resection versus Stereotactic Body Radiation Therapy as Initial Local Treatment for BCLC Stage 0 Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis
Hye In Lee, Jinhong Jung, Gil-Chun Park, Dong-Hwan Jung et al.
2026-05-28 · DOI: 10.1159/000552740Erratum
2026-05-27 · DOI: 10.1159/000551913Erratum
2026-05-27 · DOI: 10.1159/000552217Real-World Evidence from a Nationwide Prospective Study of the Efficacy/Safety of Systemic Therapy for Unresectable Hepatocellular Carcinoma: First 1,000 Patients of the PRISM Study
Masafumi Ikeda, Shinji Itoh, Daisuke Onozuka, Sadahisa Ogasawara et al.
2026-05-21 · DOI: 10.1159/000552686The China Paradox in LEAP-012 Trial
Masatoshi Kudo
2026-05-18 · DOI: 10.1159/000552537Reviews
Community Reviews
Version History
September 14, 2026 at 2:15 am
September 14, 2026